Parallel reductions of IgE and exhaled nitric oxide after optimized anti‐inflammatory asthma treatment

Immunoglobulin E (IgE) is crucial for the development of airway inflammation in atopic asthma, and inhibition of IgE using monoclonal antibodies is now part of asthma therapy. However, the impact of ordinary anti‐inflammatory treatment on IgE is unclear. The aim of this study was to investigate if o...

Full description

Saved in:
Bibliographic Details
Published in:Immunity, Inflammation and Disease Inflammation and Disease, 2016-06, Vol.4 (2), p.182-190
Main Authors: Syk, Jörgen, Malinovschi, Andrei, Borres, Magnus P., Undén, Anna‐Lena, Andreasson, Anna, Lekander, Mats, Alving, Kjell
Format: Article
Language:English
Subjects:
Allergies
Asthma
asthma control
atopy
breath test
corticosteroid
FENO
immunoglobulin E
Immunoglobulins
Inflammation
leukotriene-receptor antagonist
Medicin och hälsovetenskap
Nitric oxide
Original Research
Primary care
Quality of life
Questionnaires
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c6283-976fcaef5f3a1e4e5bcddf9dafda428d7e8a5befd2181c574236e19f154a8c993
cites cdi_FETCH-LOGICAL-c6283-976fcaef5f3a1e4e5bcddf9dafda428d7e8a5befd2181c574236e19f154a8c993
container_end_page 190
container_issue 2
container_start_page 182
container_title Immunity, Inflammation and Disease
container_volume 4
creator Syk, Jörgen
Malinovschi, Andrei
Borres, Magnus P.
Undén, Anna‐Lena
Andreasson, Anna
Lekander, Mats
Alving, Kjell
description Immunoglobulin E (IgE) is crucial for the development of airway inflammation in atopic asthma, and inhibition of IgE using monoclonal antibodies is now part of asthma therapy. However, the impact of ordinary anti‐inflammatory treatment on IgE is unclear. The aim of this study was to investigate if optimization of treatment with inhaled corticosteroid (ICS) and leukotriene‐receptor antagonist (LTRA) according to symptoms or exhaled nitric oxide (FENO) levels over a one‐year period affects IgE concentrations. Altogether, 158 relatively well‐controlled but multi‐sensitized asthmatics (age 18–65 years), with ongoing ICS treatment at baseline, were included in this post hoc analysis of data from a randomized, controlled trial on FENO‐guided asthma therapy. Asthma control and quality of life (Juniper ACQ and mAQLQ), FENO, and serum IgE were measured at baseline and after one year. Concentrations of IgE antibodies to six common perennial aeroallergens were summed up (perennial IgE). We found that perennial and total IgE decreased by 10.2% and 16.0% (P 
doi_str_mv 10.1002/iid3.103
format article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_500536</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1847893689</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6283-976fcaef5f3a1e4e5bcddf9dafda428d7e8a5befd2181c574236e19f154a8c993</originalsourceid><addsrcrecordid>eNqNksFuEzEQhlcIRKtSiSdAlrhwIGCvvbv2BalqC0SqBAfgak3W48Rldx1sL2049RH6jDwJjpqGFCkSJ4883_ya-WeK4jmjbxil5VvnDM8Rf1QclrSiE1GVzeOd-KA4jvGSUpqZhlP5tDgoG8U5q9lhsfgMAboOOxLQjG1yfojEWzKdnxMYDMHrBXRoyOBScC3x184gAZswEL9Mrne_chKG5H7f3LrBdtD3kHxYEYhp0QNJASH1OKRnxRMLXcTjzXtUfH1__uX04-Ti04fp6cnFpK1LySeqqW0LaCvLgaHAatYaY5UBa0CU0jQooZqhNSWTrK0aUfIambKsEiBbpfhRMbnTjVe4HGd6GVwPYaU9OL35-p4j1BWlFa8zr_byy-DN36L7wvLevVz7em_tmft2on2Y63HUnIqK8__D46gZF6yRGX93h2e2R9NmE_OqHjb4IDO4hZ77n1rIRolaZIFXG4Hgf4wYk-5dbLHrYEA_Rs2kaKTitVy79vIf9NKPYciLyuMqynitsltbwTb4GAPabTOM6vUt6vUt5mg964vd5rfgjnebPV25Dld7hfR0esbXgn8AUn7tCw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2290136905</pqid></control><display><type>article</type><title>Parallel reductions of IgE and exhaled nitric oxide after optimized anti‐inflammatory asthma treatment</title><source>Wiley-Blackwell Open Access Collection</source><source>PubMed Central Free</source><source>Publicly Available Content Database</source><creator>Syk, Jörgen ; Malinovschi, Andrei ; Borres, Magnus P. ; Undén, Anna‐Lena ; Andreasson, Anna ; Lekander, Mats ; Alving, Kjell</creator><creatorcontrib>Syk, Jörgen ; Malinovschi, Andrei ; Borres, Magnus P. ; Undén, Anna‐Lena ; Andreasson, Anna ; Lekander, Mats ; Alving, Kjell</creatorcontrib><description>Immunoglobulin E (IgE) is crucial for the development of airway inflammation in atopic asthma, and inhibition of IgE using monoclonal antibodies is now part of asthma therapy. However, the impact of ordinary anti‐inflammatory treatment on IgE is unclear. The aim of this study was to investigate if optimization of treatment with inhaled corticosteroid (ICS) and leukotriene‐receptor antagonist (LTRA) according to symptoms or exhaled nitric oxide (FENO) levels over a one‐year period affects IgE concentrations. Altogether, 158 relatively well‐controlled but multi‐sensitized asthmatics (age 18–65 years), with ongoing ICS treatment at baseline, were included in this post hoc analysis of data from a randomized, controlled trial on FENO‐guided asthma therapy. Asthma control and quality of life (Juniper ACQ and mAQLQ), FENO, and serum IgE were measured at baseline and after one year. Concentrations of IgE antibodies to six common perennial aeroallergens were summed up (perennial IgE). We found that perennial and total IgE decreased by 10.2% and 16.0% (P &lt; .001 both comparisons). This was not related to allergen exposure, whereas the total use of ICS and LTRA during the year correlated with the reduction in perennial IgE (P = .030 and P = .013). The decrease in perennial and total IgE correlated significantly with the reduction in FENO (P &lt; .003 and P &lt; .001), and with improvements in ACQ and mAQLQ scores (P &lt; 0.05, all comparisons). We conclude that one year of optimization of treatment with ICS and LTRA in patients with persistent atopic asthma resulted in significant decreases in total IgE and IgE antibodies; these decreases correlated with a reduction in FENO and improvements in asthma control and quality of life. Thus, IgE is reduced by ordinary asthma controller medications and the effect on IgE seems to be clinically important. This is the first study to show a parallel reduction in IgE concentrations and FeNO, a marker of Th2‐driven airway inflammation, by ordinary controller medication in patients with allergic asthma. The reduction in IgE was larger in patients showing a clinically important improvement of asthma control. We suggests that IgE measurement may be used in the long‐term follow up of anti‐inflammatory asthma treatment.</description><identifier>ISSN: 2050-4527</identifier><identifier>EISSN: 2050-4527</identifier><identifier>DOI: 10.1002/iid3.103</identifier><identifier>PMID: 27933161</identifier><language>eng</language><publisher>England: John Wiley &amp; Sons, Inc</publisher><subject>Allergies ; Asthma ; asthma control ; atopy ; breath test ; corticosteroid ; FENO ; immunoglobulin E ; Immunoglobulins ; Inflammation ; leukotriene-receptor antagonist ; Medicin och hälsovetenskap ; Nitric oxide ; Original Research ; Primary care ; Quality of life ; Questionnaires</subject><ispartof>Immunity, Inflammation and Disease, 2016-06, Vol.4 (2), p.182-190</ispartof><rights>2016 The Authors. Published by John Wiley &amp; Sons Ltd.</rights><rights>2016. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6283-976fcaef5f3a1e4e5bcddf9dafda428d7e8a5befd2181c574236e19f154a8c993</citedby><cites>FETCH-LOGICAL-c6283-976fcaef5f3a1e4e5bcddf9dafda428d7e8a5befd2181c574236e19f154a8c993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2290136905/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2290136905?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,37013,44590,46052,46476,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27933161$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-134178$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-304533$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:227933161$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Syk, Jörgen</creatorcontrib><creatorcontrib>Malinovschi, Andrei</creatorcontrib><creatorcontrib>Borres, Magnus P.</creatorcontrib><creatorcontrib>Undén, Anna‐Lena</creatorcontrib><creatorcontrib>Andreasson, Anna</creatorcontrib><creatorcontrib>Lekander, Mats</creatorcontrib><creatorcontrib>Alving, Kjell</creatorcontrib><title>Parallel reductions of IgE and exhaled nitric oxide after optimized anti‐inflammatory asthma treatment</title><title>Immunity, Inflammation and Disease</title><addtitle>Immun Inflamm Dis</addtitle><description>Immunoglobulin E (IgE) is crucial for the development of airway inflammation in atopic asthma, and inhibition of IgE using monoclonal antibodies is now part of asthma therapy. However, the impact of ordinary anti‐inflammatory treatment on IgE is unclear. The aim of this study was to investigate if optimization of treatment with inhaled corticosteroid (ICS) and leukotriene‐receptor antagonist (LTRA) according to symptoms or exhaled nitric oxide (FENO) levels over a one‐year period affects IgE concentrations. Altogether, 158 relatively well‐controlled but multi‐sensitized asthmatics (age 18–65 years), with ongoing ICS treatment at baseline, were included in this post hoc analysis of data from a randomized, controlled trial on FENO‐guided asthma therapy. Asthma control and quality of life (Juniper ACQ and mAQLQ), FENO, and serum IgE were measured at baseline and after one year. Concentrations of IgE antibodies to six common perennial aeroallergens were summed up (perennial IgE). We found that perennial and total IgE decreased by 10.2% and 16.0% (P &lt; .001 both comparisons). This was not related to allergen exposure, whereas the total use of ICS and LTRA during the year correlated with the reduction in perennial IgE (P = .030 and P = .013). The decrease in perennial and total IgE correlated significantly with the reduction in FENO (P &lt; .003 and P &lt; .001), and with improvements in ACQ and mAQLQ scores (P &lt; 0.05, all comparisons). We conclude that one year of optimization of treatment with ICS and LTRA in patients with persistent atopic asthma resulted in significant decreases in total IgE and IgE antibodies; these decreases correlated with a reduction in FENO and improvements in asthma control and quality of life. Thus, IgE is reduced by ordinary asthma controller medications and the effect on IgE seems to be clinically important. This is the first study to show a parallel reduction in IgE concentrations and FeNO, a marker of Th2‐driven airway inflammation, by ordinary controller medication in patients with allergic asthma. The reduction in IgE was larger in patients showing a clinically important improvement of asthma control. We suggests that IgE measurement may be used in the long‐term follow up of anti‐inflammatory asthma treatment.</description><subject>Allergies</subject><subject>Asthma</subject><subject>asthma control</subject><subject>atopy</subject><subject>breath test</subject><subject>corticosteroid</subject><subject>FENO</subject><subject>immunoglobulin E</subject><subject>Immunoglobulins</subject><subject>Inflammation</subject><subject>leukotriene-receptor antagonist</subject><subject>Medicin och hälsovetenskap</subject><subject>Nitric oxide</subject><subject>Original Research</subject><subject>Primary care</subject><subject>Quality of life</subject><subject>Questionnaires</subject><issn>2050-4527</issn><issn>2050-4527</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><recordid>eNqNksFuEzEQhlcIRKtSiSdAlrhwIGCvvbv2BalqC0SqBAfgak3W48Rldx1sL2049RH6jDwJjpqGFCkSJ4883_ya-WeK4jmjbxil5VvnDM8Rf1QclrSiE1GVzeOd-KA4jvGSUpqZhlP5tDgoG8U5q9lhsfgMAboOOxLQjG1yfojEWzKdnxMYDMHrBXRoyOBScC3x184gAZswEL9Mrne_chKG5H7f3LrBdtD3kHxYEYhp0QNJASH1OKRnxRMLXcTjzXtUfH1__uX04-Ti04fp6cnFpK1LySeqqW0LaCvLgaHAatYaY5UBa0CU0jQooZqhNSWTrK0aUfIambKsEiBbpfhRMbnTjVe4HGd6GVwPYaU9OL35-p4j1BWlFa8zr_byy-DN36L7wvLevVz7em_tmft2on2Y63HUnIqK8__D46gZF6yRGX93h2e2R9NmE_OqHjb4IDO4hZ77n1rIRolaZIFXG4Hgf4wYk-5dbLHrYEA_Rs2kaKTitVy79vIf9NKPYciLyuMqynitsltbwTb4GAPabTOM6vUt6vUt5mg964vd5rfgjnebPV25Dld7hfR0esbXgn8AUn7tCw</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Syk, Jörgen</creator><creator>Malinovschi, Andrei</creator><creator>Borres, Magnus P.</creator><creator>Undén, Anna‐Lena</creator><creator>Andreasson, Anna</creator><creator>Lekander, Mats</creator><creator>Alving, Kjell</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>ABAVF</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>DG7</scope><scope>ZZAVC</scope><scope>ACNBI</scope><scope>DF2</scope></search><sort><creationdate>201606</creationdate><title>Parallel reductions of IgE and exhaled nitric oxide after optimized anti‐inflammatory asthma treatment</title><author>Syk, Jörgen ; Malinovschi, Andrei ; Borres, Magnus P. ; Undén, Anna‐Lena ; Andreasson, Anna ; Lekander, Mats ; Alving, Kjell</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6283-976fcaef5f3a1e4e5bcddf9dafda428d7e8a5befd2181c574236e19f154a8c993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Allergies</topic><topic>Asthma</topic><topic>asthma control</topic><topic>atopy</topic><topic>breath test</topic><topic>corticosteroid</topic><topic>FENO</topic><topic>immunoglobulin E</topic><topic>Immunoglobulins</topic><topic>Inflammation</topic><topic>leukotriene-receptor antagonist</topic><topic>Medicin och hälsovetenskap</topic><topic>Nitric oxide</topic><topic>Original Research</topic><topic>Primary care</topic><topic>Quality of life</topic><topic>Questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Syk, Jörgen</creatorcontrib><creatorcontrib>Malinovschi, Andrei</creatorcontrib><creatorcontrib>Borres, Magnus P.</creatorcontrib><creatorcontrib>Undén, Anna‐Lena</creatorcontrib><creatorcontrib>Andreasson, Anna</creatorcontrib><creatorcontrib>Lekander, Mats</creatorcontrib><creatorcontrib>Alving, Kjell</creatorcontrib><collection>Wiley-Blackwell Open Access Collection</collection><collection>Wiley Online Library Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SWEPUB Stockholms universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Stockholms universitet</collection><collection>SwePub Articles full text</collection><collection>SWEPUB Uppsala universitet full text</collection><collection>SWEPUB Uppsala universitet</collection><jtitle>Immunity, Inflammation and Disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Syk, Jörgen</au><au>Malinovschi, Andrei</au><au>Borres, Magnus P.</au><au>Undén, Anna‐Lena</au><au>Andreasson, Anna</au><au>Lekander, Mats</au><au>Alving, Kjell</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Parallel reductions of IgE and exhaled nitric oxide after optimized anti‐inflammatory asthma treatment</atitle><jtitle>Immunity, Inflammation and Disease</jtitle><addtitle>Immun Inflamm Dis</addtitle><date>2016-06</date><risdate>2016</risdate><volume>4</volume><issue>2</issue><spage>182</spage><epage>190</epage><pages>182-190</pages><issn>2050-4527</issn><eissn>2050-4527</eissn><abstract>Immunoglobulin E (IgE) is crucial for the development of airway inflammation in atopic asthma, and inhibition of IgE using monoclonal antibodies is now part of asthma therapy. However, the impact of ordinary anti‐inflammatory treatment on IgE is unclear. The aim of this study was to investigate if optimization of treatment with inhaled corticosteroid (ICS) and leukotriene‐receptor antagonist (LTRA) according to symptoms or exhaled nitric oxide (FENO) levels over a one‐year period affects IgE concentrations. Altogether, 158 relatively well‐controlled but multi‐sensitized asthmatics (age 18–65 years), with ongoing ICS treatment at baseline, were included in this post hoc analysis of data from a randomized, controlled trial on FENO‐guided asthma therapy. Asthma control and quality of life (Juniper ACQ and mAQLQ), FENO, and serum IgE were measured at baseline and after one year. Concentrations of IgE antibodies to six common perennial aeroallergens were summed up (perennial IgE). We found that perennial and total IgE decreased by 10.2% and 16.0% (P &lt; .001 both comparisons). This was not related to allergen exposure, whereas the total use of ICS and LTRA during the year correlated with the reduction in perennial IgE (P = .030 and P = .013). The decrease in perennial and total IgE correlated significantly with the reduction in FENO (P &lt; .003 and P &lt; .001), and with improvements in ACQ and mAQLQ scores (P &lt; 0.05, all comparisons). We conclude that one year of optimization of treatment with ICS and LTRA in patients with persistent atopic asthma resulted in significant decreases in total IgE and IgE antibodies; these decreases correlated with a reduction in FENO and improvements in asthma control and quality of life. Thus, IgE is reduced by ordinary asthma controller medications and the effect on IgE seems to be clinically important. This is the first study to show a parallel reduction in IgE concentrations and FeNO, a marker of Th2‐driven airway inflammation, by ordinary controller medication in patients with allergic asthma. The reduction in IgE was larger in patients showing a clinically important improvement of asthma control. We suggests that IgE measurement may be used in the long‐term follow up of anti‐inflammatory asthma treatment.</abstract><cop>England</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>27933161</pmid><doi>10.1002/iid3.103</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2050-4527
ispartof Immunity, Inflammation and Disease, 2016-06, Vol.4 (2), p.182-190
issn 2050-4527
2050-4527
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_500536
source Wiley-Blackwell Open Access Collection; PubMed Central Free; Publicly Available Content Database
subjects Allergies
Asthma
asthma control
atopy
breath test
corticosteroid
FENO
immunoglobulin E
Immunoglobulins
Inflammation
leukotriene-receptor antagonist
Medicin och hälsovetenskap
Nitric oxide
Original Research
Primary care
Quality of life
Questionnaires
title Parallel reductions of IgE and exhaled nitric oxide after optimized anti‐inflammatory asthma treatment
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T17%3A48%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Parallel%20reductions%20of%20IgE%20and%20exhaled%20nitric%20oxide%20after%20optimized%20anti%E2%80%90inflammatory%20asthma%20treatment&rft.jtitle=Immunity,%20Inflammation%20and%20Disease&rft.au=Syk,%20J%C3%B6rgen&rft.date=2016-06&rft.volume=4&rft.issue=2&rft.spage=182&rft.epage=190&rft.pages=182-190&rft.issn=2050-4527&rft.eissn=2050-4527&rft_id=info:doi/10.1002/iid3.103&rft_dat=%3Cproquest_swepu%3E1847893689%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c6283-976fcaef5f3a1e4e5bcddf9dafda428d7e8a5befd2181c574236e19f154a8c993%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2290136905&rft_id=info:pmid/27933161&rfr_iscdi=true